Evidence map›Paper›PMID 35769830›Full record

ArticlePathology oncology research : POR2022

Characterizing HDAC Pathway Copy Number Variation in Pan-Cancer.

Shuming Yang, Shengzhi Xie, Xinying Shi, Dan Su, Bo He, Yang Xu, Zhefeng Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology oncology research : POR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shuming YangDepartment of Oncology, Senior Department of Oncology, The Third Medical Center of PLA General Hospital, Beijing, China.
Shengzhi XieDepartment of Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Xinying ShiGenecast Biotechnology Co., Ltd., Wuxi, China.
Dan SuDepartment of Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Bo HeDepartment of Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Yang XuDepartment of Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Zhefeng LiuDepartment of Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Chinese PLA General Hospital · CNGenecast (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DNA Copy Number VariationsNeoplasmsHistone DeacetylasesHumansMicrosatellite InstabilityPrognosisHistone Deacetylasescopy number variationhistone deacetylaseimmuneprognosistumor characteristics

Identifiers

PMID35769830
PMCPMC9235358
OpenAlexW4282568203

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.